Page 133 - 2021_05-Haematologica-web

Targeting A2A in CLL
References
1.Zhang S, Kipps TJ. The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol. 2014;9:103-118.
2. Burger JA, Gribben JG. The microenviron- ment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted ther- apies. Semin Cancer Biol. 2014;24:71-81.
3.Sutton LA, Rosenquist R. The complex interplay between cell-intrinsic and cell- extrinsic factors driving the evolution of chronic lymphocytic leukemia. Semin Cancer Biol. 2015;34:22-35.
4. ten Hacken E, Burger JA.Microenvironment dependency in chronic lymphocytic leukemia: the basis for new targeted thera- pies. Pharmacol Ther. 2014; 144(3):338-348.
5. ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in chronic lymphocytic leukemia: implications for disease patho- genesis and treatment. Biochim Biophys Acta. 2016;1863(3):401-413.
6.Barrientos JC. Sequencing of chronic lym- phocytic leukemia therapies. Hematology Am Soc Hematol Educ Program. 2016; 2016(1):128-136.
7. Arruga F, Deaglio S. Mechanisms of resist- ance to targeted therapies in chronic lym- phocytic leukemia. Handb Exp Pharmacol. 2018;249:203-229.
8.van Attekum MH, Eldering E, Kater AP. Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk. Haematologica. 2017; 102(9): 1469-1476.
9.Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002; 99(3):1030-1037.
10. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11(6):393-410.
11.Valsecchi R, Coltella N, Belloni D, et al. HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. Blood. 2016; 127(16): 1987-1997.
12. Bhandari V, Hoey C, Liu LY, et al. Molecular landmarks of tumor hypoxia across cancer types. Nat Genet. 2019;51(2):308-318.
13. Koczula KM, Ludwig C, Hayden R, et al. Metabolic plasticity in CLL: adaptation to
the hypoxic niche. Leukemia. 2016;
30(1):65-73.
14. Serra S, Vaisitti T, Audrito V, et al.
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. Blood Adv. 2016;1(1):47-61.
15.Beavis PA, Divisekera U, Paget C, et al. Blockade of A2A receptors potently sup- presses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A. 2013;110(36): 14711-14716.
16.Serra S, Deaglio S. HPLC-based assay to monitor extracellular nucleotide/nucleoside metabolism in human chronic lymphocytic leukemia cells. J Vis Exp. 2016;(113). doi: 10.3791/54124.
17. Klinger M, Freissmuth M, Nanoff C. Adenosine receptors: G protein-mediated signalling and the role of accessory pro- teins. Cell Signal. 2002;14(2):99-108.
18. Wen AY, Sakamoto KM, Miller LS. The role of the transcription factor CREB in immune function. J Immunol. 2010;185(11):6413- 6419.
19.Serra S, Horenstein AL, Vaisitti T, et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood. 2011;118(23):6141-6152.
20. Jak M, Mous R, Remmerswaal EB, et al. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lympho- cytic leukemia. Leuk Lymphoma. 2009; 50(5):788-801.
21. Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013; 121(9):1612-1621.
22. Jitschin R, Braun M, Buttner M, et al. CLL- cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124(5):750-760.
23. Teh BW, Tam CS, Handunnetti S, Worth LJ, Slavin MA. Infections in patients with chronic lymphocytic leukaemia: mitigating risk in the era of targeted therapies. Blood Rev. 2018;32(6):499-507.
24.Audrito V, Serra S, Brusa D, et al. Extracellular nicotinamide phosphoribosyl- transferase (NAMPT) promotes M2 macrophage polarization in chronic lympho- cytic leukemia. Blood. 2015;125(1):111-123.
25. Forconi F, Moss P. Perturbation of the nor-
26.
mal immune system in patients with CLL. Blood. 2015;126(5):573-581.
DiLillo DJ, Weinberg JB, Yoshizaki A, et al. Chronic lymphocytic leukemia and regula- tory B cells share IL-10 competence and immunosuppressive function. Leukemia. 2013;27(1):170-182.
27. Ringelstein-Harlev S, Avivi I, Fanadka M, Horowitz NA, Katz T. Chronic lymphocyt- ic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation. Cancer Immunol Immunother. 2018;67(5):739-748.
28.
Zanesi N, Aqeilan R, Drusco A, et al. Effect of rapamycin on mouse chronic lympho- cytic leukemia and the development of nonhematopoietic malignancies in Emu- TCL1 transgenic mice. Cancer Res. 2006; 66(2):915-920.
29.Hofbauer JP, Heyder C, Denk U, et al. Development of CLL in the TCL1 trans- genic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia. 2011;25(9):1452-1458.
30. McClanahan F, Hanna B, Miller S, et al. PD- L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood. 2015;126(2):203-211.
31. Hanna BS, McClanahan F, Yazdanparast H, et al. Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. Leukemia. 2016;30(3):570-579.
32. Hanna BS, Roessner PM, Yazdanparast H, et al. Control of chronic lymphocytic leukemia development by clonally-expand- ed CD8(+) T-cells that undergo functional exhaustion in secondary lymphoid tissues. Leukemia. 2019;33(3):625-637.
33.Guieze R, Liu VM, Rosebrock D, et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36(4):369- 384 e313.
34. Young A, Ngiow SF, Barkauskas DS, et al. Co-inhibition of CD73 and A2AR adeno- sine signaling improves anti-tumor immune responses. Cancer Cell. 2016; 30(3):391-403.
35. Lemal R, Tournilhac O. State-of-the-art for CAR T-cell therapy for chronic lymphocyt- ic leukemia in 2019. J Immunother Cancer. 2019;7(1):202.
haematologica | 2021; 106(5)
1353